Revenue: As of FY2025 Q4, the actual value is USD 64.45 M, beating the estimate of USD 62.82 M.EPS: As of FY2025 Q4, the actual value is USD 0.68, beating the estimate of USD 0.6636.EBIT: As of FY2025 Q4, the actual value is USD 16.78 M.<h3>Q4 2025 Financial Highlights</h3><ul><li>Sales: LeMaitre Vascular, Inc. reported sales of $64.5 million, marking a 16% increase (15% organic) compared to Q4 2024 . Net sales for the quarter were $64,453 thousand .</li><li>Gross Margin: Improved by 240 basis points to 71.7% . Gross profit was $46,190 thousand .</li><li>Operating Income: Grew by 47% to $18.8 million . Income from operations was $18,832 thousand .</li><li>Operating Margin: Stood at 29% .</li><li>Net Income: Reached $15,582 thousand .</li><li>Operational Costs: Operating expense growth was moderate at 6% .</li><li>Segment Revenue (Geographic): Americas contributed $40,169 thousand (62%), Europe, Middle East and Africa $19,691 thousand (31%), and Asia Pacific $4,593 thousand (7%) . Sales growth was primarily driven by Grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) . Geographically, EMEA sales increased by 29%, APAC by 20%, and the Americas by 10% .</li><li>Unique Metrics: Adjusted EBITDA for the quarter was $20,857 thousand, an increase of 39% .</li></ul><h3>Full Year 2025 Financial Highlights</h3><ul><li>Sales: LeMaitre Vascular, Inc. achieved 14% sales growth, with net sales totaling $249,602 thousand .</li><li>Gross Profit: Was $178,539 thousand .</li><li>Operating Income: Grew by 30% to $67,912 thousand .</li><li>Net Income: Was $57,734 thousand .</li><li>Segment Revenue (Geographic): Americas contributed $159,665 thousand (64%), Europe, Middle East and Africa $73,122 thousand (29%), and Asia Pacific $16,815 thousand (7%) .</li><li>Unique Metrics: Adjusted EBITDA for the year was $74,312 thousand, an increase of 20% . Adjusted earnings per share was $2.38, an increase of 23% from $1.93 in 2024 .</li></ul><h3>Balance Sheet Highlights (as of December 31, 2025)</h3><ul><li>Cash and Cash Equivalents: $28,244 thousand .</li><li>Total Current Assets: $468,232 thousand, including cash and cash equivalents of $28,244 thousand and short-term marketable securities of $330,876 thousand .</li><li>Total Assets: Amounted to $615,690 thousand .</li><li>Total Current Liabilities: $36,323 thousand .</li><li>Total Liabilities: Were $222,174 thousand .</li><li>Total Stockholders’ Equity: Was $393,516 thousand .</li></ul><h3>Cash Flow &amp; Capital Allocation</h3><ul><li>Cash Position: Cash increased sequentially by $16.1 million to $359.1 million .</li><li>Dividends: The Board of Directors of LeMaitre Vascular, Inc. approved a 25% increase in the quarterly dividend to $0.25 per share of common stock .</li><li>Share Repurchase: The Board also authorized the repurchase of up to $100.0 million of the company’s common stock .</li></ul><h3>Business Outlook / Guidance</h3>For Q1 2026, [勒梅特微管医疗] projects sales between $65.6 million and $67.6 million (midpoint $66.6 million, +11%, +10% organic), with operating income between $16.7 million and $18.1 million (midpoint $17.4 million, +38%) and an operating margin midpoint of 26% . For the full year 2026, sales are expected to be between $276 million and $284 million (midpoint $280 million, +12%, +12% organic), with operating income between $75.0 million and $80.7 million (midpoint $77.8 million, +15%, adjusted +21%) and an operating margin midpoint of 28% . This guidance anticipates another year of healthy sales and profit growth for [勒梅特微管医疗] .

Lemaitre Vascular | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 64.45 M